Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B - PubMed (original) (raw)

Clinical Trial

. 2004 Jan 26;90(2):372-6.

doi: 10.1038/sj.bjc.6601460.

S Secchi, E Morra, U Vitolo, E Orlandi, F Pasini, E Gallo, A Ambrosetti, C Tecchio, C Tarella, A Gabbas, A Gallamini, L Gargantini, M Pizzuti, G Fioritoni, L Gottin, G Rossi, M Lazzarino, F Menestrina, M Paulli, M Palestro, M G Cabras, F Di Vito, G Pizzolo

Affiliations

Clinical Trial

Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B

G Todeschini et al. Br J Cancer. 2004.

Abstract

The optimal treatment of primary mediastinal large B-cell lymphoma (PMLBCL) is still undefined. In the absence of randomised studies, we retrospectively analysed: (a) the effectiveness of two chemotherapy regimens (CHOP vs MACOP-B/VACOP-B) in complete remission (CR) achievement and event-free survival (EFS) and (b) the role of mediastinal involved-field radiotherapy (IF-RT) as consolidation. From 1982 to 1999, 138 consecutive patients affected by PMLBCL were treated in 13 Italian institutions with CHOP (43) or MACOP-B/VACOP-B (95). The two groups of patients were similar as regard to age, gender, presence of bulky mediastinal mass, pleural effusion, stage and international prognostic indexes category of risk. Overall, 75.5% of patients in CR received IF-RT as consolidation. Complete remission was 51.1% in the CHOP group and 80% in MACOP-B/VACOP-B (P<0.001). Relapse occurred in 22.7% of CHOP- and in 9.2% of MACOP-B/VACOP-B-treated patients (n.s.). Event-free patients were 39.5% in CHOP and 75.7% in the MACOP-B/VACOP-B group (P<0.001). The addition of IF-RT as consolidation improved the outcome, irrespectively of the type of chemotherapy (P=0.04). At a multivariate analysis, achievement of CR (P<0.0001) and type of CT (MACOP-B/VACOP-B) retained the significance for OS (P=0.008) and EFS (P=0.03). In our experience, MACOP-B/VACOP-B appears to positively influence OS and EFS in patients affected by PMLBCL, as compared to CHOP. Consolidation IF-RT on mediastinum further improves the outcome of CR patients.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Event-free survival in CHOP- vs MACOP/VACOP-B-treated patients.

Figure 2

Figure 2

Event-free survival in CR patients treated or not with IF-RT.

Similar articles

Cited by

References

    1. Abou-Ella AA, Weisenburger DD, Vose JM, Kollath JP, Lynch JC, Bast MA, Bierman PJ, Greiner TC, Chan WC, Armitage JO (1999) Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. J Clin Oncol 17: 784–790 - PubMed
    1. Addis BJ, Isaacson PG (1986) Large cell lymphoma of the mediastinum: a B-cell tumor of probable thymic origin. Histopathology 10: 379–390 - PubMed
    1. Aisenberg AC (1999) Primary large cell lymphoma of the mediastinum. Semin Oncol 26: 251–258 - PubMed
    1. Al-Sharabati M, Chittal S, Duga-Neulat I, Laurent G, Mazzerolles C, al-Saati T, Brousset P, Delsol G (1991) Primary anterior mediastinal B-cell lymphoma. A clinicopathological and immunohistochemical study of 16 cases. Cancer 67: 2579–2587 - PubMed
    1. Bertini M, Orsucci L, Vitolo U, Levis A, Todeschini G, Meneghini V, Novero D, Tarella C, Gallo E, Luxi G (1991) Stage II large B-cell lymphoma with sclerosis treated with MACOP-B. Ann Oncol 2: 733–737 - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources